智飞生物
(300122)
| 流通市值：291.35亿 | | | 总市值：493.12亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 7,627,406,876.36 | 4,919,216,833.15 | 2,374,498,616.11 | 26,069,711,361.44 |
| 营业收入 | 7,627,406,876.36 | 4,919,216,833.15 | 2,374,498,616.11 | 26,069,711,361.44 |
| 二、营业总成本 | 8,661,709,184.38 | 5,343,407,811.4 | 2,434,178,574.47 | 23,192,418,166.64 |
| 营业成本 | 5,814,018,774.53 | 3,524,904,961.35 | 1,610,053,156.46 | 18,931,449,180.34 |
| 税金及附加 | 47,938,068.85 | 31,964,389.96 | 12,249,068.99 | 135,447,961.03 |
| 销售费用 | 1,615,337,616.85 | 1,043,682,141.91 | 429,766,771.06 | 2,650,685,785.78 |
| 管理费用 | 292,324,625.19 | 179,079,388.39 | 88,481,190.63 | 394,131,628.41 |
| 研发费用 | 668,694,285.13 | 419,057,232.21 | 227,359,676.59 | 971,365,516.55 |
| 财务费用 | 223,395,813.83 | 144,719,697.58 | 66,268,710.74 | 109,338,094.53 |
| 其中:利息费用 | 243,905,920.61 | 150,269,981.61 | 70,046,267.69 | 146,853,557.49 |
| 其中:利息收入 | 21,016,967.62 | 15,654,632.45 | 6,997,310.84 | 66,627,336.29 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -7,777,347.26 | 2,355,610.36 | -1,928,650.82 | - |
| 加:投资收益 | 13,903.16 | - | - | - |
| 资产处置收益 | 5,818,931.18 | 5,815,453.17 | 6,354,306.43 | 46,946.97 |
| 资产减值损失(新) | -125,441,769.61 | -70,188,825.68 | -38,336,112.34 | -39,539,833.44 |
| 信用减值损失(新) | -378,208,047.39 | -316,587,627.9 | -252,152,677.35 | -615,800,939.66 |
| 其他收益 | 27,833,751.77 | 19,594,253.91 | 13,012,999.37 | 41,812,908.21 |
| 四、营业利润 | -1,512,062,886.17 | -783,202,114.39 | -332,730,093.07 | 2,263,812,276.88 |
| 加:营业外收入 | 97,369.65 | 22,562.32 | 22,162.3 | 69,496 |
| 减:营业外支出 | 1,322,706.32 | 1,086,203.24 | 409,212.47 | 10,190,202 |
| 五、利润总额 | -1,513,288,222.84 | -784,265,755.31 | -333,117,143.24 | 2,253,691,570.88 |
| 减:所得税费用 | -293,811,509.27 | -187,170,164.45 | -27,976,549.96 | 235,213,056.97 |
| 六、净利润 | -1,219,476,713.57 | -597,095,590.86 | -305,140,593.28 | 2,018,478,513.91 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -1,219,476,713.57 | -597,095,590.86 | -305,140,593.28 | 2,018,478,513.91 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -1,206,414,751.26 | -597,095,590.86 | -305,140,593.28 | 2,018,478,513.91 |
| 少数股东损益 | -13,061,962.31 | - | - | - |
| 扣除非经常损益后的净利润 | -1,226,745,301.26 | -619,848,706.85 | -319,662,743.68 | 1,991,386,516.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.5 | -0.25 | -0.13 | 0.84 |
| (二)稀释每股收益 | -0.5 | -0.25 | -0.13 | 0.84 |
| 九、综合收益总额 | -1,219,476,713.57 | -597,095,590.86 | -305,140,593.28 | 2,018,478,513.91 |
| 归属于母公司股东的综合收益总额 | -1,206,414,751.26 | -597,095,590.86 | -305,140,593.28 | 2,018,478,513.91 |
| 归属于少数股东的综合收益总额 | -13,061,962.31 | - | - | - |
| 公告日期 | 2025-10-30 | 2025-08-19 | 2025-04-22 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |